Partners Group Private Equity Reports Strong Liquidity Despite NAV Decline

Earnings
โดย GuruFocus·GB·Read original
Summary · why it matters

Partners Group Private Equity Ltd reported strong liquidity generation with approximately EUR111 million in distributions, equivalent to around 14% of net assets, despite a challenging market environment, while its NAV declined by 8.6% on a total return basis in H1 2026. The company highlighted successful realizations, including the full sale of Clario to Thermo Fisher Scientific and full sell-down of Galderma, with last 12-month exits achieving a money multiple close to 3x invested capital. However, four assets—USIC, Emeria, Pharmathen, and Amega—accounted for approximately two-thirds of the portfolio decline, with Pharmathen written down to zero following an FDA import alert. Younger vintages (2024-2025 investments) are performing well, with blended IRR around 20%, and AI initiatives across the portfolio show an adoption rate of about 90% with $170 million of visible EBITDA opportunities for 2027. The company returned almost EUR36 million through dividends and share buybacks in H1 2026, with a prospective dividend yield above 8%, and expects proceeds realized over the next 6 to 12 months to trend towards the high teens as a percentage of NAV.

Impact on stocks 2

Health Care▲ · 1 stocks
Biotech & Genomic Medicine▲ · 1 stocks

Off-coverage companies 5

PharmathenPrivate▼ Negative
Regulationrelevance

Pharmathen was written down to zero following an FDA import alert.

USICPrivate▼ Negative
Capitalrelevance

USIC is named as one of four assets accounting for roughly two-thirds of the portfolio's decline.

Ammega GroupPrivate▼ Negative
Capitalrelevance

Ammega is named as one of four assets accounting for about two-thirds of the portfolio decline.

EmeriaPrivate▼ Negative
Capitalrelevance

Emeria is named as one of four assets driving roughly two-thirds of the portfolio decline.

Clario HoldingsPrivate± Mixed
Capitalrelevance

Clario was fully sold to Thermo Fisher, a realization event for the private equity holder, not a company-specific development.

© 2026 MarketDXNews